newsfilter
← Interviews
Milken Institute1h 4m

Combatting the Crisis of Opioids

Sabrina Spitaletta, Alan M. Muney, Joe Smyser, Nora Volkow, Greg Walden, James A. Winnefeld, Jr.

Panel, Conference Presentation

Crisis Origins and Evolution

  • Root Cause: The crisis originated from a well-intentioned healthcare initiative to treat the 100 million Americans suffering from pain, driven by a lack of non-opioid alternatives and overconfidence in opioid efficacy.
  • Clinical Misconception: Physicians initially underestimated the risk of addiction, operating under the false belief that patients using opioids for legitimate pain management would not develop substance use disorders.
  • The Three Waves: The epidemic has evolved through three distinct phases:
    • Phase 1: Over-prescription of pharmaceutical opioids created a supply for diversion and addiction.
    • Phase 2: As prescription rates fell, users transitioned to cheaper, more accessible heroin.
    • Phase 3: The rise of synthetic opioids, specifically fentanyl, which is cheaper to synthesize, easier to smuggle, and requires smaller volumes due to extreme potency.
  • Fatality Trends: Fentanyl-related fatalities have surged from approximately 200–300 seven years ago to 20,000 currently.
  • Broader Context: While opioids are the focus, fatal overdoses from cocaine are also rising rapidly, indicating a need for a holistic national drug strategy rather than an opioid-only approach.

Personal Impact and Strategic Frameworks

  • Personal Tragedy: Admiral Winnefeld lost his son, Jonathan, a 25-year-old EMT and college student, to a relapse four days after completing 15 months of recovery.
  • Admiral Winnefeld's Seven Lines of Operation:
    • Public Awareness: Combating stigma and building political support for recovery.
    • Prevention: Full-spectrum prevention across schools, colleges, and workplaces.
    • Prescription Management: Addressing irresponsible prescribing by doctors, dentists, and the pharmaceutical industry.
    • Law Enforcement & Medical Response: Integrating "warm handoffs" from overdose scenes to treatment and focusing on the fact that 85% of drug arrests are for possession.
    • Treatment & Recovery: Addressing the critical shortage of affordable, high-quality treatment.
    • Family Support: Supporting families during the high-risk transition from inpatient care to community reintegration.
    • Community-Level Action: Promoting "Safe Communities" and "Safe Campuses" to decentralize solutions from the federal level.

Legislative and Policy Actions

  • Committee Investigations: The Energy and Commerce Committee is investigating the "epicenter" of West Virginia, where millions of hydrocodone pills were distributed to towns with populations in the hundreds (e.g., 9 million pills in Kermit, WV, a town of 406 people).
  • Socioeconomic Reach: The crisis affects all demographics, with New Hampshire ranking second only to West Virginia, proving the issue transcends economic status.
  • Legislative Output: Over 60 pieces of legislation have emerged from committee discussions, with 56 bills already marked up.
  • Enforcement Priorities:
    • Addressing the entry of synthetic fentanyls through the US Postal Service.
    • Updating laws to stay ahead of chemists creating new synthetic molecules faster than regulatory schedules can classify them.
  • Healthcare Reform: Legislation aims to treat addiction as a chronic disease rather than a crime, breaking down silos in data sharing between providers and expanding access to Medication-Assisted Treatment (MAT) via telemedicine.
  • Medicaid/Medicare Evolution: Proposals to modernize funding structures to support newer treatment modalities like telemedicine and expanded Suboxone prescribing.

Healthcare Industry Response and Data

  • Cigna's Holistic Approach: Cigna integrated behavioral, medical, and pharmacy programs to treat substance abuse as a chronic condition, resulting in a 25% reduction in opioid prescriptions among their physician network.
  • Paradoxical Increase: Despite reducing prescriptions by 25%, Cigna recorded a 19% increase in overdoses last year; notably, only 40% of these overdose patients had a Cigna prescription for opioids on file.
  • Naloxone Access: Cigna advocates for deploying Naloxone (Narcan) at all locations with Automated External Defibrillators (AEDs) and has already successfully utilized a citizen-administered dose to revive a passenger on a commercial flight.
  • Data Gaps: Dr. Nora Volkow highlighted critical missing data regarding the distinction between overdose deaths caused by intentional suicidal behavior versus accidental overdose in pain management.
  • Quality Metrics: There is currently no standardized data on treatment program outcomes, leading to a proliferation of low-quality programs; quality metrics are needed to incentivize better care.

Communication, Stigma, and Demographics

  • Communication Gaps: Messaging often fails to resonate with specific demographics:
    • 18–25 Year Olds: Almost entirely missed by prevention campaigns despite being the peak age of initial opioid experimentation.
    • Rural Communities: Receive messaging tailored to urban contexts, ignoring their specific conceptualization of the crisis.
    • Over 45s: Engage with the topic primarily through the lens of chronic pain.
  • Stigma Dynamics: Stigma is more prevalent among older generations; younger generations (Millennials/Gen Z) are more willing to discuss addiction openly and seek help.
  • Language Matters: Shifting terminology from "addict" and "clean/dirty" to "person with a chronic illness" changes physician attitudes and improves patient follow-up care.
  • The "College Cliff": A critical gap exists in prevention and support systems for the transition from high school to college, where opioid uptake significantly increases.
  • Family-Centric Treatment: Emerging models, such as those in Denver, allow mothers to receive treatment while keeping their children, removing a major barrier to seeking help.

Prevention and Future Directions

  • Preventive Strategies: Effective prevention requires alignment of the right message, messengers, mediums, timing, and audience; current efforts are failing to reach the specific "moments of need" in a user's journey from pain to addiction.
  • Alternative Pain Management: Evidence suggests traditional anti-inflammatories (e.g., Tylenol) can be as effective as opioids for pain, yet physicians are still incentivized to prescribe opioids due to outdated cultural norms and lack of reimbursement for non-opioid pain management.
  • Prescription Tracking: Legislation is advancing to improve Prescription Drug Monitoring Programs (PDMPs), enable e-prescribing, and allow pharmacists to refuse filling suspicious prescriptions.
  • Community Action: Successful local models include "turn-in-and-treat" programs at sheriff's offices (e.g., Illinois) and fire departments (e.g., New Hampshire) that guarantee immediate transport to treatment upon surrendering drugs.
  • Call to Action: The crisis requires a shift from punitive justice to a public health model, demanding individual community involvement, better data transparency, and a rejection of the "siloed" approach to treatment.